Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Immunogenicity and Safety of Vaccination Against Tick Borne Encephalitis (TBE) in Patients Living With Multiple Sclerosis (MS) (MS and TBE vac)

17 novembre 2026 mis à jour par: Insel Gruppe AG, University Hospital Bern

This is a monocenter, prospective cohort study. The study investigates the response of patients living with multiple sclerosis (MS) to vaccination against tick-borne viral encephalitis (TBE).

The prevalence of TBE has increased significantly in Switzerland over the past two decades. Whereas previously only the lowland regions of northern Switzerland and the Aare Valley were considered areas where TBE vaccination was indicated, the disease is now endemic throughout Switzerland (except for Ticino). Since TBE specifically affects the nervous system, there is a clear indication for vaccination, particularly for people whose nervous system is already compromised.

MS is the most common neurological autoimmune disease among young adults in northern latitudes. It is a progressive disease characterized by a gradual deterioration of neurological functions. The course of the disease can be slowed through immunomodulatory therapies. However, these therapies also lead to a certain degree of immunosuppression, which may reduce the immune response to vaccinations. At the same time, some people with MS experience fear or scepticism towards vaccinations, as infections often lead to a worsening of symptoms or can trigger a relapse. Since vaccinations mimic an infection to some extent, this concern is sometimes transferred to vaccinations as well.

The study hypothesizes that the TBE vaccine in people living with MS on non-B-cell depleting treatment shows adequate immunogenicity.

Moreover, the study will assess the safety of TBE vaccination.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Type d'étude

Observationnel

Inscription (Estimé)

50

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Bern, Suisse, 3010
        • Recrutement
        • University Hospital of Bern
        • Contact:
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

The investigators target a sample size of 50 people living with MS with stable RRMS (no evidence of disease activity -NEDA-3 status - as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI) for ≥ 1 year prior to inclusion into the study and treated with non-B-cell depleting therapies for at least 6 months in monotherapy.

In order to have a homogenous and stable patient population, the investigators decided to include only patients without evidence of disease activity for at least 1 year prior to inclusion. Considering the latter the investigators classify any disease reactivation during the period of 42 days (+/- 7days) after the first dose / booster dose as related to the intervention (vaccination).

La description

Inclusion Criteria

  • Adult (≥ 18 years old)

  • Suspected neuroimmunological disorder with CNS affection

    • including suspicion of Multiple Sclerosis (MS)
    • Diagnosed Multiple Sclerosis (MS)
    • Clinically Isolated Syndrome
    • Radiologically Isolated Syndrome
  • stable RRMS - defined as no evidence of disease activity-NEDA-3 status-as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI for ≥ 1 year prior to inclusion

  • treated with non-B-cell depleting therapies for at least 6 months in monotherapy

  • TBE vaccine:

    • never been vaccinated against TBE or
    • clinical indication for booster vaccination (person living with MS and has had primary series of 3 vaccines of which the last one was ≥ 10 years ago)
  • Provided written informed consent

Exclusion Criteria

  • Any B-cell depleting therapies in last 12 months prior to recruitment
  • Any other vaccination in last 2 months prior to recruitment
  • Any foreseeable and necessary other vaccination up to 42 days post dose 1
  • Immunoglobulin-Infusion (intravenous or subcutaneous, IVIG or SCIG) in the last 4 months prior to the drawing of study samples

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Primary vaccination series or Booser against TBE in patients with MS

According to Swiss guidelines, patients with MS will receive the primary vaccination series (3 doses) against TBE (if they have never been vaccinated) or a TBE booster (if they have already received the primary vaccination series and their last vaccination was ≥ 10 years ago).

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Primary immunogenicity endpoint
Délai: 42 days post dose 1

Change in antibody concentration (GMC) from baseline to day 42 post dose 1 as measured by ELISA

42 days post dose 1

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Immunogenicity endpoint
Délai: 42 days post dose 1

Change in antibody titers as measured by serum neutralizing test (SNT) from baseline to day 42 (post dose 1)

42 days post dose 1
Immunogenicity endpoint
Délai: 7 months post dose 1 or 6 months post booster dose

Change in antibody titers as measured by ELISA from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.

7 months post dose 1 or 6 months post booster dose
Immunogenicity endpoint
Délai: 7 months post dose 1 or 6 months post booster dose

Change in antibody titers as measured by SNT from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.

7 months post dose 1 or 6 months post booster dose
Immunogenicity endpoint
Délai: at each time point (7 months)

Seropositivity as measured by ELISA . Seropositivity is defined as IgG antibody concentration >150 U/ml for ELISA.

at each time point (7 months)
Immunogenicity endpoint
Délai: at each time point (7 months)

Seropositivity as measured by SNT at each time point. Seropositivity is defined as antibody titer >1:10 for SNT.

at each time point (7 months)
Safety endpoint
Délai: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Incidence of MS-relapses - defined clinically, according to clinical expert judgement, by the presence of MS-typical symptoms with objectifiable findings lasting more than 24 hours, without fever or infection.

42 (+/-7d) post dose 1
Safety endpoint
Délai: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Activity in cerebral MRI scan (new or enlarging lesions or gadolinium uptake)

42 (+/-7d) post dose 1
Safety endpoint
Délai: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Neurological assessment (EDSS)

42 (+/-7d) post dose 1
Safety endpoint
Délai: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Multivariable blood biomarker based scores for MS disease activity (MSDA) and disease pathways (Octave Bioscience, USA)

42 (+/-7d) post dose 1
Safety endpoint
Délai: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Vaccine reactogenicity (solicited and unsolicited local and systemic vaccine reactions)

42 (+/-7d) post dose 1

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

22 avril 2026

Achèvement primaire (Estimé)

31 mai 2027

Achèvement de l'étude (Estimé)

31 mai 2027

Dates d'inscription aux études

Première soumission

28 août 2026

Première soumission répondant aux critères de contrôle qualité

17 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 novembre 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner